Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $45 at Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts HRMY Hot Sheet
Price: $38.49 -0.03%
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 24 | New: 16
Rating Summary:
12 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 24 | New: 16
Join SI Premium – FREE
Needham analyst Ami Fadia raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $45.00 (from $44.00) while maintaining a Buy rating.
You May Also Be Interested In
- Exlservice (EXLS) PT Raised to $48 at Stifel
- Expand Energy (EXE) PT Lowered to $113 at Freedom Broker
- Establishment Labs Inc. (ESTA) PT Lowered to $93 at BTIG
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
